1|0|Public
50|$|<b>Ebalzotan</b> (NAE-086) is a {{selective}} 5-HT1A receptor agonist. It was under development as an antidepressant and anxiolytic agent but produced undesirable side effects in phase I clinical trials and was subsequently discontinued.|$|E

